Clinical Trial: Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT07453602) titled 'Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234' on March 02.

Brief Summary: This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD). Healthy volunteers will participate in Single Ascending Dose (SAD) Cohorts 1-5. Participants with moderate to severe AD will be enrolled in SAD Cohorts 6-7, Multiple Ascending Dose (MAD) Coh...